Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RBC Bioscience's Enterprise Value is NT$636.2 Mil.
RBC Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$17.9 Mil. Therefore, RBC Bioscience's EV-to-EBIT ratio for today is 35.59.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, RBC Bioscience's Enterprise Value is NT$636.2 Mil.
RBC Bioscience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$37.1 Mil. Therefore, RBC Bioscience's EV-to-EBITDA ratio for today is 17.16.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, RBC Bioscience's Enterprise Value is NT$636.2 Mil.
RBC Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$172.5 Mil. Therefore, RBC Bioscience's EV-to-Revenue ratio for today is 3.69.
RBC Bioscience Enterprise Value Historical Data
The historical data trend for RBC Bioscience's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RBC Bioscience's Enterprise Value
For the Biotechnology subindustry, RBC Bioscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's Enterprise Value distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's Enterprise Value falls into.
RBC Bioscience Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
RBC Bioscience's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience (ROCO:6848) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
RBC Bioscience's current Enterprise Value is NT$636.2 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$17.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
RBC Bioscience's current Enterprise Value is NT$636.2 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$37.1 Mil.
RBC Bioscience's current Enterprise Value is NT$636.2 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$172.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience Enterprise Value Related Terms
Thank you for viewing the detailed overview of RBC Bioscience's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6848 has been successfully added to your 